Program 60: Cancer Risk, Prevention, and Early Detection

癌症风险、预防和早期检测计划 项目摘要/摘要 癌症风险、预防和早期检测(CARPED)计划的使命是减少 癌症负担：(A)围绕癌症发生和发展的关键时期开展广泛的研究 以及(B)设计临床上有效的策略，在高危人群中拦截这一过程。这个 该计划的范围从普通人群到高危人群再到癌症前期患者 损伤或靶向突变。 CARPED是从以前的癌症风险和差异(CARD)计划演变而来的一个新计划。它的 使命依赖于利用DF/HCC在癌症生物学、流行病学、预防和癌症科学方面的专业知识 实施，以及波士顿生态系统在技术创新方面的广度和深度。这个 该计划致力于将科学进步和知识传播转化为 可持续的基于社区的做法以及减少与癌症有关的差异。培训一位新的 一代具有跨学科、量化、临床、技术和实施技能的研究人员 是一个重要的计划重点。 我们的86名成员(55名小学和31名中学)代表了所有7个DF/HCC机构和17个学术机构 各部门。2019年，用于该方案的同行评审赠款资金为570万美元 来自NCI的670万美元和其他赞助商的670万美元。在本资助期内，PRIMARY 成员发表了914篇与癌症相关的论文。其中，23%是机构间的，9%是机构内的 方案，43%是两个或更多DF/CC成员之间的方案间协作。 这些数字反映了由计划和高级DF/CC管理的计划间互动的广度 与癌症中心的战略计划保持密切一致的领导人。 在下一个CCSG资助期，该计划的具体目标是：1)开发和验证新的 癌症前期和早期癌症检测技术，2)开发个性化和精确的方法 使用风险评估和癌症前期和早期癌症检测的新技术拦截癌症， 以及3)通过多学科团队应用个性化和精确化的方法来拦截癌症。 DF/HCC在跨学科协作、创新临床试验、社区方面的广泛基础设施 参与、共享资源、教育和培训将有助于实现这些具体目标。

Cancer Risk, Prevention, and Early Detection Program Project Summary / Abstract The mission of the Cancer Risk, Prevention, and Early Detection (CaRPED) Program is to decrease the burden of cancer by (a) focusing a broad array of research around the critical period of cancer initiation and early growth, and (b) devising clinically effective strategies to intercept this process among people at risk. The Program’s scope ranges from the general population to high-risk groups to individuals with pre-cancerous lesions or targetable mutations. CaRPED is a new Program that evolved from a previous Program in Cancer Risk and Disparities (CaRD). Its mission relies on leveraging DF/HCC expertise in cancer biology, epidemiology, prevention, and the science of implementation, together with the breadth and depth of the Boston ecosystem for technological innovation. The Program is committed to the translation of scientific advances and the dissemination of knowledge into sustainable community-based practices as well as the alleviation of cancer-related disparities. Training a new generation of researchers with transdisciplinary, quantitative, clinical, technological, and implementation skills is an important Program focus. Our 86 members (55 primary and 31 secondary) represent all seven DF/HCC institutions and 17 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $5.7 million in direct costs from the NCI and $6.7 million from other sponsors. During the current funding period, primary CaRPED members published 914 cancer-relevant papers. Of these, 23% were inter-institutional, 9% were intra- programmatic, and 43% were inter-programmatic collaborations between two or more DF/HCC members. These numbers reflect the breadth of inter-Program interactivity stewarded by Program and senior DF/HCC leaders in close alignment with the Cancer Center’s strategic plan. For the next CCSG funding period, the Program’s Specific Aims are to 1) develop and validate new technologies for pre-cancer and early cancer detection, 2) develop personalized and precision approaches for cancer interception using new technologies for risk assessment and pre-cancer and early cancer detection, and 3) apply personalized and precision approaches for cancer interception through multidisciplinary teams. DF/HCC’s extensive infrastructure for transdisciplinary collaboration, innovative clinical trials, community engagement, shared resources, education, and training will be instrumental in achieving these concrete goals.